Jose Perez del Palacio
MEDINA Foundation, Spain
Title: Predictive biomarker discovery of treatment response in lung cancer: A metabolomic approach
Biography
Biography: Jose Perez del Palacio
Abstract
Although the broad range of chemotherapeutic agents approved in the late years, it is a challenge for oncologists to choose which drug or combination of drugs will represent the best option for each individual, since only a portion of patients will respond properly. In this regard a biomarker approach to predict patient response to treatment may be very helpful in the making decision process. Metabolomics, the unbiased identifi cation and quantifi cation of small molecule metabolites in biological samples, is particularly promising for biomarker development because altered metabolism is considered a hallmark of cancer. In this work, we have investigated the metabolome of 115 plasma samples from lung cancer patients by mean of liquid chromatography high resolution mass spectrometry. Th e obtained data matrix was analyzed according the clinical response to each therapy (Neoadjuvant and Inmunotherapy) in order to search for a predictive molecular signature in each group of patients.